Zyprexa Fines Irrelevant In Actos Trial, Eli Lilly Says

Law360, New York (March 7, 2014, 5:25 PM EST) -- Eli Lilly & Co. argued Thursday that the first federal bellwether trial over the bladder cancer risks of diabetes drug Actos should exclude evidence about its fines for marketing the antipsychotic drug Zyprexa, saying it’s not relevant to negligent marketing claims over Actos. 

In a response filed to the Louisiana federal court, Eli Lilly argued that the fines over Zyprexa stemmed from misdemeanor criminal violations, and not any finding of negligence. Its response followed a demand for sanctions earlier this week by plaintiffs Terrence and Susan...
To view the full article, register now.